Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-Arm, phase II trial

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages 3219-3225

  Li, Jin ^a   Qin, Shukui ^d   Xu, Jianming ^f   Guo, Weijian ^a   Xiong, Jianping ^g   Bai, Yuxian ^h   Sun, Guoping ⁱ   Yang, Yan ^j   Wang, Liwei ^b   Xu, Nong ^k   Cheng, Ying ^l   Wang, Zhehai ^m   Zheng, Leizhen ^c   Tao, Min ⁿ   Zhu, Xiaodong ^a   Ji, Dongmei ^a   Liu, Xin ^a   Yu, Hao ^e  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^c XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d 81 Hospital of PLA   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

^f BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^g NANCHANG UNIVERSITY   (China)

^h HARBIN MEDICAL UNIVERSITY   (China)

ⁱ ANHUI MEDICAL UNIVERSITY   (China)

^j Gansu Cancer Hospital   (China)

^k ZHEJIANG UNIVERSITY   (China)

^l Jilin Provincial Hospital of Cancer   (China)

^m SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

ⁿ THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; APATINIB; PLACEBO; UNCLASSIFIED DRUG; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RISK ASSESSMENT; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INTERRUPTION; VOMITING; ADOLESCENT; CANCER STAGING; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DRUG RESISTANCE; FOLLOW UP; INTERNATIONAL COOPERATION; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PERITONEAL NEOPLASMS; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SECONDARY; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PROGNOSIS; PYRIDINES; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84891373220     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.8585     Document Type: Article

References (16)

1. Thuss-Patience PC, Hofheinz RD, Arnold D, et al: Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol 23:2827-2834, 2012.
2. Kang JH, Lee SI, Lim do H, et al: Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513-1518, 2012.
3. Hawkes E, Okines AF, Papamichael D, et al: Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. Eur J Cancer 47:1146-1151, 2011.
4. Park SH, Kim YS, Hong J, et al: Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: A noncomparative phase II study. Anticancer Drugs 19:303-307, 2008.
5. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31, 1995.
6. Tanigawa N, Amaya H, Matsumura M, et al: Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol 15:826-832, 1997.
7. Bang YJ, Kang YK, Kang WK, et al: Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 29:1449- 1458, 2011.
8. Kang Y, Ohtsu A, Van Cutsem, E, et al: AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 28:240s, 2012 (suppl; abstr LBA4007).
9. Van Cutsem, E, de Haas, S, Kang YK, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30:2119-2127, 2012.
10. Fuchs CS, Tomasek J, Cho JY, et al: REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum-And/or fluoropyrimidine-containing combination therapy. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA, January 24-26, 2013 (abstr LBA5).
11. Tian S, Quan H, Xie C, et al: YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Science 102: 1374-1380, 2011.
12. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004.
13. Li J, Zhao X, Chen L, et al: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 10:529, 2010.
14. Zhao H, Kanda K: Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res 9:129-137, 2000.
15. Lee J, Lim T, Uhm JE, et al: Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18:886-891, 2007.
16. Rino Y, Yukawa N, Wada N, et al: Phase II study of S-1 monotherapy as a first-line, combination therapy of S-1 plus cisplatin as a second-line, and weekly paclitaxel monotherapy as a third-line therapy in patients with advanced gastric carcinoma. Clin Med Oncol 2:375-383, 2008.